more

Eli Lilly (LLY)

(Delayed Data from NYSE)

$770.00 USD

-1.12 (-0.15%)

Updated May 17, 2024 04:00 PM ET

After-Market: $770.30 +0.30 (0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.08%
2	Buy	17.91%
3	Hold	9.44%
4	Sell	5.10%
5	Strong Sell	2.55%
S&P	500	11.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5 3

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth A Momentum B VGM

Industry Rank:

Bottom 24% (190 out of 249)

Industry: Large Cap Pharmaceuticals

View All Zacks #1 Ranked Stocks

Better trading starts here.

Research for LLY

Annual Key Company Metrics
Quarterly Key Company Metrics

Revenue - Line of Business Segments	YR Estimate	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019
Net Sales: Immunology [$M]		3,798	3,345	3,361	2,462	1,793
Net Sales: Emgality (Galcanezumab...		678	651	577	363	163
Net Sales: Diabetes Total [$M]		19,668	14,465	13,188	11,834	11,132
Net Sales: Neuroscience: Other Ne...		227	125	95	--	--
Net Sales: Oncology: Retevmo [$M]		254	192	115	--	--
Net Sales: Oncology: Tyvyt [$M]		393	293	418	--	--
Net Sales: Diabetes: Other [$M]		530	497	--	--	--
Net Sales: Oncology: Other Oncolo...		613	424	--	--	--
Net sales: Other - Other - Total ...		1,122	3,520	--	--	--
Net Sales: Diabetes: Mounjaro -To...		5,163	483	--	--	--
Net Sales: Neurosciences [$M]		2,879	1,546	1,899	1,831	1,723
Net Sales: Oncology [$M] [$M]		6,658	5,666	5,741	5,319	4,614
Net sales: Other pharmaceuticals ...		1,122	3,520	4,130	3,093	3,057
Net Sales: Cialis [$M] [$M]		381	587	718	607	891
Net Sales: Cymbalta [$M] [$M]		243	283	582	768	725
Net Sales: Erbitux [$M] [$M]		597	567	548	536	543
Net Sales: Forteo [$M] [$M]		533	613	802	1,046	1,405
Net sales: Trajenta [$M]		387	384	373	359	591
Net Sales: Trulicity (Dulaglutide...		7,133	7,440	6,472	5,068	4,128
Net Sales: Humalog [$M] [$M]		1,663	2,061	2,453	2,626	2,821
Net Sales: Taltz (Ixekizumab / LY...		2,760	2,482	2,213	1,789	1,366
Net Sales: Alimta [$M] [$M]		218	928	2,061	2,330	2,116
Net Sales: Jardiance (Empaglifloz...		2,745	2,066	1,491	1,154	944
Net Sales: Verzenio- Total [$M]		3,863	2,484	1,350	913	580
Net Sales: Humulin [$M] [$M]		852	1,019	1,223	1,260	1,290
Net Sales: Olumiant/Baricitinib (...		923	831	1,115	639	427
Net Sales: Cyramza (Ramucirumab /...		975	971	1,033	1,033	925
Net Sales: Basaglar (LY2963016 / ...		728	760	893	1,124	1,113
Revenue - Geographic Segments	YR Estimate	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019
Net Sales: Cyramza (Ramucirumab /...		402	351	358	382	335
Net Sales: Cyramza (Ramucirumab /...		572	620	675	651	79
Net Sales: Trulicity (Dulaglutide...		5,433	5,689	4,914	4	3,155
Net Sales: Trulicity (Dulaglutide...		1,699	1,751	1,558	1	232
Net Sales: Jardiance (Empaglifloz...		1,600	1,195	807	621	566
Net Sales: Jardiance (Empaglifloz...		1,144	872	684	533	139
Net Sales: Olumiant/Baricitinib (...		226	148	324	64	42
Net Sales: Olumiant/Baricitinib (...		697	682	791	49	28
Net Sales: Taltz (Ixekizumab / LY...		1,832	1,725	1,542	1	1,017
Net Sales: Taltz (Ixekizumab / LY...		928	757	670	500	64
Net Sales: Basaglar (LY2963016 / ...		443	471	588	842	876
Net Sales: Verzenio- US [$M]		2,509	1,653	835	618	125
Net Sales: Emgality (Galcanezumab...		482	463	435	618	8
Net Sales: Emgality (Galcanezumab...		196	188	143	37	8
Net Sales: Verzenio- ROW [$M]		1,354	830	515	294	125
Net Sales: Diabetes- United State...		14,781	9,911	8,719	--	--
Net Sales: Diabetes- Outside U.S ...		4,887	4,554	4,469	--	--
Net Sales: Oncology- United State...		3,797	3,218	--	2,792	2,609
Net Sales: Oncology- Outside U.S ...		2,861	2,448	--	2,527	2,006
Net Sales: Immunology- United Sta...		2,058	1,893	1,882	1,372	1,059
Net Sales: Immunology- Outside U....		1,740	1,452	1,479	1,090	734
Net Sales: Neuroscience- United S...	--	696	612	615	487	357
Net Sales: Neuroscience- Outside ...		2,183	934	1,284	1,344	1,366
Net Sales: Other pharmaceuticals:...		459	2,556	547	1,668	1,169
Net Sales: Other pharmaceuticals:...		663	964	781	1,424	1,888
Revenue: Neuroscience: Retevmo: U...	--	175	143	103	--	--
Revenue: Neuroscience: Retevmo: O...	--	78	49	24	--	--
Net Sales: Oncology: Tyvyt - Outs...		393	293	418	--	--
Net Sales: Oncology: Erbitux - U....		529	500	361	--	--
Net Sales: Oncology: Erbitux - Ou...		68	66	47	--	--
Net Sales: Oncology: Other Oncolo...		34	170	120	--	--
Net Sales: Oncology: Other Oncolo...		147	254	211	--	--
Revenue to unaffiliated customers...		--	--	7,708	--	--
Net Sales: Diabetes: Other - U.S....		175	158	--	--	--
Revenue: Diabetes: Other - Outsid...		355	339	--	--	--
Net Sales: Other: Other -U.S. [$M...		459	2,556	--	--	--
Net Sales: Other: Other -Outside ...		663	964	--	--	--
Net Sales: Diabetes: Mounjaro -U....		4,834	367	--	--	--
Net Sales: Diabetes: Mounjaro -Ou...		329	116	--	--	--
Net Sales: Other Neuroscience: Ot...		134	119	102	--	--
Net Sales: Other Neuroscience- Ou...		371	439	208	--	--
Net Sales: US-Cialis [$M] [$M]		26	35	11	--	232
Net Sales: US-Cymbalta [$M] [$M]		31	34	39	--	50
Net Sales: US-Humulin [$M] [$M]		610	730	833	866	880
Net Sales: International-Cialis [...		678	651	708	--	659
Net Sales: International-Cymbalt...		--	250	543	--	676
Net Sales: International-Humulin ...		242	289	390	393	410
Geographic Revenue: China [$M]		1,540	1,453	1,661	1,117	939
Geographic Revenue: United States...		21,791	18,190	16,811	14,229	12,723
Geographic Revenue: Europe [$M]		6,175	4,299	4,777	4,188	3,765
Geographic Revenue: Japan [$M]		1,673	1,747	2,367	2,583	2,548
Net Sales: US-Humalog [$M] [$M]		863	1,192	1,321	1	1,670
Net Sales: US-Alimta [$M] [$M]		73	544	1,234	1	1,220
Net Sales: US-Forteo [$M] [$M]	--	336	367	442	510	646
Geographic Revenue: Other foreign...		2,946	2,852	2,702	2,423	2,345
Net Sales: Basaglar (LY2963016 / ...		285	290	304	282	65
Net Sales: International-Humalog ...		800	869	1,132	1	1,151
Net Sales: International-Alimta [...		145	384	828	1	896
Net Sales: International-Forteo [...		198	246	360	536	759

Revenue - Line of Business Segments	Qtr Estimate	03/31/2024	12/31/2023	09/30/2023	06/30/2023	03/31/2023
Net Sales: Immunology [$M]		834	1,104	987	929	778
Net Sales: Emgality (Galcanezumab...		834	58	169	169	154
Net Sales: Diabetes Total [$M]		5,493	5,746	4,720	5,011	4,190
Net Sales: Neuroscience: Other Ne...		101	68	48	59	53
Net Sales: Oncology: Retevmo [$M]		69	73	63	65	51
Net Sales: Oncology: Tyvyt [$M]		117	114	115	104	61
Net Sales: Diabetes: Other [$M]		35	36	47	33	28
Net Sales: Oncology: Other Oncolo...		49	47	48	52	34
Net sales: Other - Other - Total ...		242	34	43	35	21
Net Sales: Diabetes: Mounjaro -To...		1,807	2,206	1,409	980	569
Net Sales: Neurosciences [$M]		389	363	1,768	387	361
Net Sales: Oncology [$M] [$M]		1,810	1,884	1,747	1,671	1,356
Net sales: Other pharmaceuticals ...	--	242	256	276	315	275
Net Sales: Cialis [$M] [$M]		139	79	87	116	100
Net Sales: Cymbalta [$M] [$M]		54	57	61	64	60
Net Sales: Erbitux [$M] [$M]		145	150	154	163	130
Net Sales: Forteo [$M] [$M]		61	116	146	148	122
Net sales: Trajenta [$M]		89	102	95	104	86
Net Sales: Trulicity (Dulaglutide...		1,456	1,669	1,674	1,813	1,977
Net Sales: Humalog [$M] [$M]		539	367	395	440	461
Net Sales: Taltz (Ixekizumab / LY...		604	785	744	704	527
Net Sales: Alimta [$M] [$M]		70	45	54	61	58
Net Sales: Jardiance (Empaglifloz...		687	798	701	668	578
Net Sales: Verzenio- Total [$M]		1,050	1,145	1,040	927	751
Net Sales: Humulin [$M] [$M]		206	188	207	205	252
Net Sales: Olumiant/Baricitinib (...		217	244	231	219	229
Net Sales: Cyramza (Ramucirumab /...		230	254	224	260	237
Net Sales: Basaglar (LY2963016 / ...		158	185	180	154	209
Revenue - Geographic Segments	Qtr Estimate	03/31/2024	12/31/2023	09/30/2023	06/30/2023	03/31/2023
Net Sales: Cyramza (Ramucirumab /...		107	99	88	115	101
Net Sales: Cyramza (Ramucirumab /...		123	155	136	145	136
Net Sales: Trulicity (Dulaglutide...		1,082	1,256	1,259	1,371	1,547
Net Sales: Trulicity (Dulaglutide...		374	414	415	441	430
Net Sales: Jardiance (Empaglifloz...		368	469	416	386	329
Net Sales: Jardiance (Empaglifloz...		318	329	285	282	248
Net Sales: Olumiant/Baricitinib (...		46	67	66	51	42
Net Sales: Olumiant/Baricitinib (...		171	177	166	168	187
Net Sales: Taltz (Ixekizumab / LY...		347	538	509	472	312
Net Sales: Taltz (Ixekizumab / LY...		257	247	235	232	215
Net Sales: Basaglar (LY2963016 / ...		83	113	111	83	135
Net Sales: Verzenio- US [$M]		1,050	775	685	589	461
Net Sales: Emgality (Galcanezumab...		125	128	127	119	109
Net Sales: Emgality (Galcanezumab...		101	186	42	51	46
Net Sales: Verzenio- ROW [$M]		412	371	356	338	290
Net Sales: Diabetes- United State...		4,090	4,464	3,460	3,781	3,075
Net Sales: Diabetes- Outside U.S ...		1,403	1,282	1,260	1,230	1,115
Net Sales: Oncology- United State...		998	1,107	1,002	935	753
Net Sales: Oncology- Outside U.S ...		812	777	746	736	603
Net Sales: Immunology- United Sta...		397	605	575	523	355
Net Sales: Immunology- Outside U....		437	499	412	405	423
Net Sales: Neuroscience- United S...		163	183	207	161	145
Net Sales: Neuroscience- Outside ...		226	180	1,561	226	216
Net Sales: Other pharmaceuticals:...		46	96	124	131	109
Net Sales: Other pharmaceuticals:...		196	161	152	184	167
Revenue: Neuroscience: Retevmo: U...		45	52	42	44	36
Revenue: Neuroscience: Retevmo: O...		24	21	21	21	15
Net Sales: Oncology: Tyvyt - Outs...		117	114	115	104	61
Net Sales: Oncology: Erbitux - U....		132	131	134	146	119
Net Sales: Oncology: Erbitux - Ou...		13	20	20	17	11
Net Sales: Oncology: Other Oncolo...		12	30	16	43	14
Net Sales: Oncology: Other Oncolo...		37	38	32	42	39
Revenue to unaffiliated customers...		3,074	--	4,131	2,781	2,524
Net Sales: Diabetes: Other - U.S....		11	21	33	17	14
Revenue: Diabetes: Other - Outsid...		24	15	14	16	14
Net Sales: Other: Other -U.S. [$M...		46	7	18	20	5
Net Sales: Other: Other -Outside ...		196	27	25	15	16
Net Sales: Diabetes: Mounjaro -U....		1,520	2,105	1,277	916	536
Net Sales: Diabetes: Mounjaro -Ou...		286	101	132	64	32
Net Sales: Other Neuroscience: Ot...		28	30	31	16	14
Net Sales: Other Neuroscience- Ou...		73	38	87	43	39
Net Sales: US-Cialis [$M] [$M]		6	5	5	9	8
Net Sales: US-Cymbalta [$M] [$M]		6	7	8	8	8
Net Sales: US-Humulin [$M] [$M]		153	122	146	144	199
Net Sales: International-Cialis [...		133	74	82	106	93
Net Sales: International-Cymbalt...		49	50	53	57	52
Net Sales: International-Humulin ...		53	67	61	61	53
Geographic Revenue: China [$M]		376	--	391	399	373
Geographic Revenue: United States...		5,694	6,455	5,368	5,531	4,436
Geographic Revenue: Europe [$M]		1,441	--	2,569	1,178	1,091
Geographic Revenue: Japan [$M]		364	--	391	456	387
Net Sales: US-Humalog [$M] [$M]		338	168	194	230	272
Net Sales: US-Alimta [$M] [$M]		15	14	21	18	20
Net Sales: US-Forteo [$M] [$M]		22	66	101	97	71
Geographic Revenue: Other foreign...		893	2,898	780	749	673
Net Sales: Basaglar (LY2963016 / ...		--	72	68	71	74
Net Sales: International-Humalog ...		200	199	201	211	189
Net Sales: International-Alimta [...		55	31	32	43	38
Net Sales: International-Forteo [...		40	50	45	51	52

Member Sign In

Member Sign In

Services Overview

Investor Services

Other Services

Trading Services

Innovators